An updated patent review of TEAD modulators (2022-present)
文献类型：期刊论文
| 作者 | Xu, Dounan1,2; Zhong, Jiahuan1,2; Zeng, Yuhan2,3; Zhang, Xianhui2,4; Wang, Chengyu2,5; Luo, Cheng1,2,3,6; Xiong, Huan2 |
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2025-07-05 |
| 页码 | 27 |
| 关键词 | Hippo signaling pathway transcriptional enhanced associated domain (TEAD) modulators anti-cancer drugs degraders combination therapy |
| ISSN号 | 1354-3776 |
| DOI | 10.1080/13543776.2025.2522747 |
| 英文摘要 | IntroductionThe Transcriptional Enhanced Associated Domain (TEAD) family has attracted increasing attention due to its crucial role in the Hippo signaling pathway, which regulates cell growth, division, survival, differentiation, and tissue homeostasis in multicellular organisms. Inhibition of TEADs with small molecules has been shown to be an effective strategy for the treatment of tumors, and several compounds have entered clinical trials as monotherapy and/or combination therapy.Areas coveredDue to the explosion of patent disclosures on TEAD modulators (inhibitors or degraders) in the last two years, this review focuses on the published patent literature on small molecule inhibitors or degraders of TEAD and their applications from June 2022 to present (March 2025), as a complementary update to the previous patent review (2018-2022).Expert opinionThe reported TEAD modulators can be categorized into 4 types: non-covalent inhibitors, covalent inhibitors, protein-protein interaction inhibitors and degraders. Meanwhile, the combination therapy with TEAD inhibitors and other kinases or mutated gene inhibitors has shown promising therapeutic effects in patients with various types of cancer, which has greatly expanded the application field of TEAD inhibitors in disease treatment. |
| WOS关键词 | TUMOR-SUPPRESSOR ; PROMOTES RESISTANCE ; INHIBITORS ; YAP/TAZ ; GROWTH ; KINASE ; KRAS ; MEK |
| 资助项目 | the National Natural Science Foundation of China[2019B090904008] ; High-level new RD institute[2021B0909050003] ; High-level Innovative Research Institute ; Department of Science and Technology of Guangdong Province[2021B1515420002] ; Guangdong Basic and Applied Basic Research Foundation |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001522627600001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321027]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Luo, Cheng; Xiong, Huan |
| 作者单位 | 1.Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Peoples R China 2.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528437, Peoples R China 3.Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China 4.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China 5.Zunyi Med Univ, Sch Pharm, Zhuhai Campus, Zhuhai, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xu, Dounan,Zhong, Jiahuan,Zeng, Yuhan,et al. An updated patent review of TEAD modulators (2022-present)[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2025:27. |
| APA | Xu, Dounan.,Zhong, Jiahuan.,Zeng, Yuhan.,Zhang, Xianhui.,Wang, Chengyu.,...&Xiong, Huan.(2025).An updated patent review of TEAD modulators (2022-present).EXPERT OPINION ON THERAPEUTIC PATENTS,27. |
| MLA | Xu, Dounan,et al."An updated patent review of TEAD modulators (2022-present)".EXPERT OPINION ON THERAPEUTIC PATENTS (2025):27. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。